Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ventyx Biosciences Inc (VTYX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: VTYX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -51.19% | Avg. Invested days 27 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 85.69M USD | Price to earnings Ratio - | 1Y Target Price 12 |
Price to earnings Ratio - | 1Y Target Price 12 | ||
Volume (30-day avg) 777188 | Beta 0.58 | 52 Weeks Range 1.07 - 5.66 | Updated Date 04/1/2025 |
52 Weeks Range 1.07 - 5.66 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.88 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -33.48% | Return on Equity (TTM) -54.27% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -124372788 | Price to Sales(TTM) - |
Enterprise Value -124372788 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -22.93 | Shares Outstanding 71130096 | Shares Floating 49589028 |
Shares Outstanding 71130096 | Shares Floating 49589028 | ||
Percent Insiders 4.46 | Percent Institutions 84.53 |
Analyst Ratings
Rating 4.22 | Target Price 11.14 | Buy 1 | Strong Buy 5 |
Buy 1 | Strong Buy 5 | ||
Hold 3 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ventyx Biosciences Inc
Company Overview
History and Background
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative medicines for autoimmune and inflammatory diseases. Founded in 2020, the company rapidly advanced its pipeline through strategic acquisitions and internal development programs.
Core Business Areas
- TYK2 Inhibitor Program: Development of oral, selective allosteric TYK2 inhibitors for the treatment of autoimmune and inflammatory diseases like psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis.
- S1P1R Modulator Program: Development of S1P1R modulators for the treatment of autoimmune diseases, potentially offering differentiated safety and efficacy profiles.
- NLRP3 Inhibitor Program: Development of NLRP3 inhibitors to target inflammatory conditions driven by the NLRP3 inflammasome.
Leadership and Structure
Ventyx is led by a management team with experience in drug development and commercialization. The company has a board of directors providing strategic oversight.
Top Products and Market Share
Key Offerings
- VAY736 (TYK2 inhibitor): VAY736 is an oral, selective allosteric TYK2 inhibitor currently in clinical development for psoriasis, psoriatic arthritis, and Crohn's disease. Competing TYK2 inhibitors include BMS's Sotyktu (deucravacitinib) and Takeda's TAK-279.
- VTX3232 (S1P1R modulator): VTX3232 is an oral S1P1R modulator being developed for autoimmune diseases. Competitors include Novartis' Gilenya (fingolimod), Bristol Myers Squibb's Zeposia (ozanimod), and Johnson & Johnson's Ponvory (ponesimod).
- VTX2735 (NLRP3 inhibitor): VTX2735 is a peripherally restricted NLRP3 inhibitor targeting inflammatory conditions. Competitors in NLRP3 inhibition are numerous, including large pharma pursuing systemic NLRP3 inhibitors.
Market Dynamics
Industry Overview
The autoimmune and inflammatory disease market is a large and growing market with unmet medical needs. The industry is characterized by high research and development costs and complex regulatory pathways.
Positioning
Ventyx aims to differentiate itself by developing oral, selective inhibitors and modulators with improved safety and efficacy profiles. Their approach targets specific pathways involved in autoimmune and inflammatory diseases.
Total Addressable Market (TAM)
The TAM for autoimmune and inflammatory disease therapies is estimated to be over $100 billion annually. Ventyx aims to capture a significant portion of this market by addressing unmet needs with its novel therapies.
Upturn SWOT Analysis
Strengths
- Strong pipeline of clinical-stage assets
- Experienced management team
- Targeting large and growing market
- Differentiated approach with oral, selective inhibitors
Weaknesses
- Clinical trial risks and potential setbacks
- Reliance on successful development and commercialization
- Competition from established pharmaceutical companies
- High cash burn rate
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approvals
Threats
- Failure to demonstrate efficacy in clinical trials
- Adverse safety events
- Regulatory delays or rejection
- Competition from new therapies
Competitors and Market Share
Key Competitors
- BMY
- NVS
- JNJ
- TAK
Competitive Landscape
Ventyx faces competition from established pharmaceutical companies with greater resources and established market presence. Ventyx aims to differentiate itself through innovative therapies and strategic partnerships.
Major Acquisitions
Oppilan Pharma
- Year: 2022
- Acquisition Price (USD millions): 105
- Strategic Rationale: Expanded Ventyx's pipeline with an oral peripherally restricted NLRP3 inhibitor program for inflammatory diseases.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's relatively recent founding.
Future Projections: Future growth is dependent on the successful development and commercialization of its pipeline assets. Analyst estimates vary based on clinical trial outcomes and regulatory approvals.
Recent Initiatives: Recent initiatives include advancing clinical trials for VAY736, VTX3232 and VTX2735 and expanding the pipeline through strategic acquisitions.
Summary
Ventyx Biosciences is a clinical-stage biopharmaceutical company with a promising pipeline focused on autoimmune and inflammatory diseases. The company's success hinges on positive clinical trial outcomes and successful commercialization. They face significant competition from established pharmaceutical companies, but their differentiated approach offers potential advantages. Ventyx needs to continue to execute its clinical programs and secure partnerships to enhance its market position.
Similar Companies
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
NVS
Novartis AG ADR
NVS
Novartis AG ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
TAK
Takeda Pharmaceutical Co Ltd ADR
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Company press releases
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual risk tolerance and due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ventyx Biosciences Inc
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2021-10-21 | Founder, CEO, President & Director Dr. Raju S. Mohan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 79 | Website https://ventyxbio.com |
Full time employees 79 | Website https://ventyxbio.com | ||
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for Crohn's disease. It is also developing Tamuzimod, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor that is in Phase 2a trial for patients with early Parkinson's disease and is in Phase 2 trial for patients with obesity and additional risk factors for cardiovascular disease. Ventyx Biosciences, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.